Yu Jonathan Yen-Wen 4
4 · Disc Medicine, Inc. · Filed Nov 13, 2025
Insider Transaction Report
Form 4
Yu Jonathan Yen-Wen
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-11$2.65/sh+30,000$79,500→ 70,555 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-11−30,000→ 7,941 totalExercise: $2.65Exp: 2030-08-10→ Common Stock (30,000 underlying) - Sale
Common Stock
2025-11-11$83.15/sh−8,015$666,410→ 62,540 total - Sale
Common Stock
2025-11-11$83.99/sh−4,585$385,084→ 57,955 total - Sale
Common Stock
2025-11-11$85.33/sh−9,360$798,690→ 48,595 total - Sale
Common Stock
2025-11-11$85.91/sh−8,040$690,740→ 40,555 total
Footnotes (6)
- [F1]The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 22, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.63 to $83.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.63 to $84.62, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.69 to $85.68, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.69 to $86.28, inclusive.
- [F6]The shares underlying this option are fully vested and exercisable as of the date hereof.